Substance / Medication

Tacrine

Overview

Active Ingredient
tacrine
RxNorm CUI
10318

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
WITHDRAWN: Tacrine for Alzheimer's disease.
Qizilbash N, Birks J, Lopez Arrieta J et al. · Cochrane Database Syst Rev · 2007
PMID: 17636619Meta-Analysis
Tacrine for Alzheimer's disease.
Qizilbash N, Birks J, López-Arrieta J et al. · Cochrane Database Syst Rev · 2000
PMID: 10796507Meta-AnalysisFull text (PMC)
Tacrine for Alzheimer's disease.
Qizilbash N, Birks J, Lopez Arrieta J et al. · Cochrane Database Syst Rev · 2000
PMID: 10908463Meta-Analysis
Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets.
Costa Nunes Fernanda, Silva Letícia Barros, Winter Evelyn et al. · Biochim Biophys Acta Gen Subj · 2018
PMID: 29704527Observational
The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat.
Yip Lian Yee, Aw Chiu Cheong, Lee Sze Han et al. · Hepatology · 2018
PMID: 28646502Observational
Novel tacrine analogs as potential cholinesterase inhibitors in Alzheimer's disease.
El-Malah Afaf, Gedawy Ehab M, Kassab Asmaa E et al. · Arch Pharm (Weinheim) · 2014
PMID: 24343873Observational
Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride.
Corace Giuseppe, Angeloni Cristina, Malaguti Marco et al. · J Liposome Res · 2014
PMID: 24807822Observational
Development, characterization and application of in situ gel systems for intranasal delivery of tacrine.
Qian Shuai, Wong Yin Cheong, Zuo Zhong · Int J Pharm · 2014
PMID: 24709220Observational
Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer's disease.
Chen Yao, Sun Jianfei, Peng Sixun et al. · Arch Pharm (Weinheim) · 2013
PMID: 24203864Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tacrine (substance)
SNOMED CT
373727000
UMLS CUI
C0039245
RxNorm CUI
10318

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.